Erasca, Inc. (ERAS)

US — Healthcare Sector
Peers: IPSC  NGM  KROS  GLUE  GRCL  THRX  DSGN  EWTX  CCCC  MLYS  CGEM  SANA  OLMA  LIFE  ZNTL  RLAY  STOK  PLRX  BDTX  ARVN 

Automate Your Wheel Strategy on ERAS

With Tiblio's Option Bot, you can configure your own wheel strategy including ERAS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ERAS
  • Rev/Share 0.0
  • Book/Share 0.141
  • PB 11.5572
  • Debt/Equity 0.1272
  • CurrentRatio 12.352
  • ROIC -0.3394

 

  • MktCap 461757810.0
  • FreeCF/Share -0.0381
  • PFCF -4.2826
  • PE -29.2968
  • Debt/Assets 0.1078
  • DivYield 0
  • ROE -0.3656

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 2
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ERAS Raymond James -- Outperform -- $5 March 26, 2025

News

Erasca, Inc.: Carving A Different Niche In RAS Signaling
ERAS
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company's lead program, naporafenib, shows preliminary efficacy in NRAS-mutant melanoma, with key phase 3 data expected in 2025. Financially stable with a cash runway into at least 2027, Erasca can advance its pipeline without immediate funding concerns, mitigating dilution risk.

Read More
image for news Erasca, Inc.: Carving A Different Niche In RAS Signaling

About Erasca, Inc. (ERAS)

  • IPO Date 2021-07-16
  • Website https://www.erasca.com
  • Industry Biotechnology
  • CEO Dr. Jonathan E. Lim M.D.
  • Employees 103
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.